# Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma

> **NCT04903119** · PHASE1 · RECRUITING · sponsor: **Rina Plattner** · enrollment: 30 (estimated)

## Conditions studied

- Metastatic Melanoma
- BRAF Gene Mutation

## Interventions

- **DRUG:** Nilotinib 100mg
- **DRUG:** Nilotinib 200mg
- **DRUG:** Nilotinib 300mg
- **DRUG:** Nilotinib 400mg
- **DRUG:** Dabrafenib
- **DRUG:** Trametinib
- **DRUG:** Encorafenib
- **DRUG:** Binimetinib

## Key facts

- **NCT ID:** NCT04903119
- **Lead sponsor:** Rina Plattner
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-06-01
- **Primary completion:** 2028-07-01
- **Final completion:** 2030-06-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-02-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04903119

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04903119, "Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT04903119. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*